Sigilon Therapeutics to Participate in Three Upcoming Investor Conferences

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, August 7, 2020
Information
Tags: 
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Diabetes, Clinical trials, Science and technology awards, Scientists, Lemelson–MIT Prize, Robert S. Langer, Awards
Geotags: 
United States, NEW YORK, Massachusetts
⚠ generated by AI ↴
Organisation: 
SIGILON THERAPEUTICS
Summary
Key Points: 
  • Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.
  • Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform.
  • The engineered cells are protected by Sigilons Afibromer biomaterials matrix, which shields them from immune rejection and fibrosis.
  • Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.


Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.

Presentation Details:

Event: BTIG Virtual Biotechnology Conference

Date: Monday, August 10, 2020

Time: 9:00 AM ET

Details: Fireside chat

Event: Canaccord Genuity 40th Annual Growth Conference

Date: Thursday, August 13, 2020

Time: 1:30 PM ET

Details: Corporate presentation

Event: Oppenheimer Private Life Sciences Company Call Series

Date: Wednesday, August 19, 2020

Time: 9:30 AM ET

Details: Corporate presentation

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Copyright: 
Copyright Business Wire 2020